Aurobindo Pharma gets USFDA's approval for Esomeprazole Magnesium DR Capsules

17 Oct 2017 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg. Esomeprazole Magnesium Delayed-Release Capsules OTC, a therapeutic equivalent generic version of AstraZeneca’s Nexium 24HR Capsules. The product will be launched immediately.

Nexium 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week). The approved product has an approximate annual sale in excess of $300 million.

This is the 127th ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. The company now has a total of 335 ANDA approvals (296 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1087.10 -27.80 (-2.49%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.